Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?

Insider Monkey2024-11-28

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Royalty Pharma (NASDAQ:RPRX) stands against other cheapest stocks to buy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486564874?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XZvi9_Jzsy7NmUdEvIXgRg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/117a6ec6167a30d9b152e441b74eca5d","is_english":true,"pubTime":"2024-11-28 00:11","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2486564874","market":"us","top_or_hot":-1,"title":"Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?","media":"Insider Monkey","content":"<div>\n<p>We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Royalty Pharma (NASDAQ:RPRX) stands against other cheapest stocks to buy ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-royalty-pharma-rprx-cheapest-161148049.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 00:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-royalty-pharma-rprx-cheapest-161148049.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Royalty Pharma (NASDAQ:RPRX) stands against other cheapest stocks to buy ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-royalty-pharma-rprx-cheapest-161148049.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/why-royalty-pharma-rprx-cheapest-161148049.html","article_id":"2486564874","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XZvi9_Jzsy7NmUdEvIXgRg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/117a6ec6167a30d9b152e441b74eca5d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486564874","pubTimestamp":1732723908,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Royalty Pharma  stands against other cheapest stocks to buy on Robinhood.While the market has been on an upward trajectory for nearly two years now, the combination of seasonal trends, strong retail, and corporate activity, and positive market momentum following the November election still suggests a potential for continued growth in U.S. equities.Goldman Sachs’ Scott Rubner predicts a year-end rally that will push the S&P to 6,200 points as reported by Bloomberg on November 25. He attributes this potential rally to growing retail enthusiasm in equities and crypto, seasonal trading patterns, and increasing corporate buyback demand.Rubner noted that the recent consolidation phase is typical, and highlighted significant inflows into U.S. equities, with the broader market gaining over 3% since the November 5 presidential vote and the Russell 2000 rising 6.5%. Histo","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4007":"制药","SQQQ":"纳指三倍做空ETF","QLD":"纳指两倍做多ETF","RPRX":"Royalty Pharma plc","HOOD":"Robinhood","BK4127":"投资银行业与经纪业","QID":"纳指两倍做空ETF","BK4547":"WSB热门概念",".IXIC":"NASDAQ Composite","BK4539":"次新股","LU1861558580.USD":"日兴方舟颠覆性创新基金B","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF"},"translate_title":"为什么Royal Pharma(RPRX)是Robinhood上最便宜的股票？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOOD":1,"RPRX":1,".IXIC":0.9,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where Royalty Pharma (NASDAQ:RPRX) stands against other cheapest stocks to buy on Robinhood.\nWhile the market has been on an upward trajectory for nearly two years now, the combination of seasonal trends, strong retail, and corporate activity, and positive market momentum following the November election still suggests a potential for continued growth in U.S. equities.\nGoldman Sachs’ Scott Rubner predicts a year-end rally that will push the S&P to 6,200 points as reported by Bloomberg on November 25. He attributes this potential rally to growing retail enthusiasm in equities and crypto, seasonal trading patterns, and increasing corporate buyback demand.\nRubner noted that the recent consolidation phase is typical, and highlighted significant inflows into U.S. equities, with the broader market gaining over 3% since the November 5 presidential vote and the Russell 2000 rising 6.5%. Historically, strong market performance in election years tends to extend into January, with the capital being deployed at the start of the new year.\nREAD ALSO: Jim Cramer’s Lightning Round: 9 Stocks in Spotlight and 10 Best Renewable Energy Penny Stocks to Invest In.\nStrategic Investment Moves in a Shifting Economy\nIn an interview with Seana Smith and Madison Mills of Yahoo Finance, Jim Smigiel, SEI’s Chief Investment Officer, highlighted several key insights for investors, in light of President-elect Donald Trump’s pro-growth policies. He warned that these policies could lead to higher inflation and rising interest rates, which may impact investment strategies. For investors, the focus should be on understanding how inflation and rates can affect different assets and staying prepared for potential shifts in the market.\nSmigiel sees opportunities in small-cap stocks, value stocks, and financials, which are expected to benefit from the current reflationary environment. He suggested investors consider diversifying their portfolios to reduce reliance on highly concentrated growth sectors like tech. Active management, where professional fund managers select investments, could also be a useful strategy to broaden exposure and adapt to market changes.\nWhile higher rates could eventually pose challenges, Smigiel noted that small-cap stocks remain attractive for now due to improved debt structures, providing a window of opportunity until around 2026. Investors should keep an eye on rising yields, as it might signal a need to shift toward more defensive investments. Diversification remains critical in managing risks during this period.\nOur Methodology\nFor this article, we checked all the large-cap companies trading on Robinhood with at least 50% positive analyst ratings. We narrowed our list to nearly 40 stocks that were trading below a forward price-to-earnings multiple of under 15. We also skipped the stocks that were trading above or at their industry median despite trading below a PE ratio of 15. Finally, we chose the 10 cheapest stocks to buy based on their average analyst price target upside as of November 25 (pre-market open). These stocks are also popular among hedge funds.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A scientist in a laboratory looking through a microscope, surrounded by petri dishes and beakers while researching new biopharmaceutical advances. \nRoyalty Pharma plc (NASDAQ:RPRX)\nMarket Cap: $16.2 billion\nFWD PE Ratio: 6.66\nAverage Price Target Upside: 58.91%\nRoyalty Pharma plc (NASDAQ:RPRX) is a key player in funding biopharmaceutical innovation and the largest acquirer of biopharmaceutical royalties. It collaborates with a wide range of partners, including academic institutions, research hospitals, non-profits, biotechnology firms, and major pharmaceutical companies.\nThe company earns royalties based on the sales of leading therapies in its portfolio, which includes over 35 commercial products and 15 development-stage candidates. Royalty Pharma (NASDAQ:RPRX) reported strong performance for Q3 2024 on November 6, with 15% growth in both Portfolio Receipts and Royalty Receipts. Year-to-date capital deployment reached $2.6 billion, including acquisitions of royalties on three novel therapies. Recent highlights include royalties on Cobenfy for schizophrenia, Voranigo for glioma, and Tremfya for ulcerative colitis, all expected to boost long-term growth.\nRoyalty Pharma (NASDAQ:RPRX) maintains strong financial capacity with $3 billion in available financial resources, including $950 million in cash and equivalents at the end of Q3, ongoing business-generated cash, and access to debt markets. The company holds $7.8 billion in investment-grade debt, with a 3.1% average cost and a 12-year average maturity, aligned with its royalty portfolio duration. Its leverage ratio is approximately 3x total debt to adjusted EBITDA, and it also has $1.8 billion in undrawn credit capacity.\nOverall, RPRX ranks 1st on our list of cheapest stocks to buy on Robinhood. While we acknowledge the potential of RPRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RPRX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock\nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486564874"}